Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 10/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 10/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763320 | 0.88 | CTSL (0.37) | — | |
| SCHEMBL6406632 | 0.87 | TAS1R3 (0.51) | TAS1R3TAS1R1UTS2RBACE1ALDH1A1 | |
| SCHEMBL4765376 | 0.86 | CTSK (0.31) | — | |
| SCHEMBL6590804 | 0.85 | CTSL (0.31) | — | |
| SCHEMBL7422805 | 0.82 | POLB (0.35) | ALDH1A1 | |
| SCHEMBL4767092 | 0.81 | CTSK (0.44) | TAS1R3TAS1R1UTS2R | |
| SCHEMBL4763006 | 0.81 | NPC1 (0.36) | ALDH1A1LMNAMAPTL3MBTL1HSD17B10 | |
| SCHEMBL4766715 | 0.81 | CTSK (0.37) | TAS1R3TAS1R1 | |
| SCHEMBL4768775 | 0.80 | GRN (0.45) | — | |
| SCHEMBL4766746 | 0.80 | CAPN1 (0.34) | ALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1320370-A1 | METHOD OF TREATMENT | SmithKline Beecham Corporation (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002017924-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-03-07 | — | — | WO | disclosed |